Monique Hinchcliff1, Saira Khanna2, Vivien M Hsu3, Jungwha Lee4, Orit Almagor5, Rowland W Chang6, Virginia Steen7, Lorinda Chung8. 1. Department of Medicine, Northwestern University Feinberg School of Medicine, 240 E Huron St, McGaw Pavilion Suite M300, Chicago, IL 60611; Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: m-hinchcliff@northwestern.edu. 2. Harvard University, Cambridge, MA. 3. Department of Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ. 4. Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 5. Department of Medicine, Northwestern University Feinberg School of Medicine, 240 E Huron St, McGaw Pavilion Suite M300, Chicago, IL 60611. 6. Department of Medicine, Northwestern University Feinberg School of Medicine, 240 E Huron St, McGaw Pavilion Suite M300, Chicago, IL 60611; Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 7. Department of Medicine, Georgetown University, Washington, DC. 8. Department of Medicine, Stanford University and Palo Alto VA Health Care System, Palo Alto, CA.
Abstract
OBJECTIVE: To determine the association between serum autoantibodies and survival in patients with incident systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. METHODS: Patients with definite PAH diagnosed by right heart catheterization within 6 months of registry enrollment were studied. Serum autoantibodies were assayed at each participating institution's clinical laboratory. Mortality data were collected from electronic medical records and/or the Social Security Death Index. Kaplan-Meier survival estimates were reported for five autoantibody groups (anticentromere/AC, nucleolar ANA/NUC, anti-topoisomerase/Scl-70, overlapping or non-specific autoantibodies/other, and a combined group with similar survival consisting of RNA polymerase III, U1RNP, and autoantibody-negative patients). Cox proportional hazards models permitted examination of the association between autoantibody groups and overall survival, controlling for age, sex, race, and SSc disease duration. RESULTS: In all, 162 subjects had PAH, and serum autoantibody and survival information; 60 (37%) had AC, 39 (24%) NUC, 11 (7%) Scl-70, 28 (17%) had other, 9 (6%) RNA pol, 8 (5%) U1RNP autoantibodies, and 7 (4%) had negative antibodies; 32 (20%) subjects died over a median follow-up time of 2.1 years (range: 0.01-6.8); 1- and 3-year survival estimates were, respectively, 94% and 78% for AC, 94% and 72% for NUC, 89% and 63% for Scl-70, 92% and 79% for the other group, and 100% and 93% for the combined group. Unadjusted and adjusted hazard ratios revealed no statistically significant association between risk of death and autoantibodies. CONCLUSION: Anticentromere and NUC autoantibodies are prevalent in SSc-PAH patients. An association between serum autoantibodies and survival in patients with SSc-PAH was not identified in the PHAROS cohort.
OBJECTIVE: To determine the association between serum autoantibodies and survival in patients with incident systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. METHODS:Patients with definite PAH diagnosed by right heart catheterization within 6 months of registry enrollment were studied. Serum autoantibodies were assayed at each participating institution's clinical laboratory. Mortality data were collected from electronic medical records and/or the Social Security Death Index. Kaplan-Meier survival estimates were reported for five autoantibody groups (anticentromere/AC, nucleolar ANA/NUC, anti-topoisomerase/Scl-70, overlapping or non-specific autoantibodies/other, and a combined group with similar survival consisting of RNA polymerase III, U1RNP, and autoantibody-negative patients). Cox proportional hazards models permitted examination of the association between autoantibody groups and overall survival, controlling for age, sex, race, and SSc disease duration. RESULTS: In all, 162 subjects had PAH, and serum autoantibody and survival information; 60 (37%) had AC, 39 (24%) NUC, 11 (7%) Scl-70, 28 (17%) had other, 9 (6%) RNA pol, 8 (5%) U1RNP autoantibodies, and 7 (4%) had negative antibodies; 32 (20%) subjects died over a median follow-up time of 2.1 years (range: 0.01-6.8); 1- and 3-year survival estimates were, respectively, 94% and 78% for AC, 94% and 72% for NUC, 89% and 63% for Scl-70, 92% and 79% for the other group, and 100% and 93% for the combined group. Unadjusted and adjusted hazard ratios revealed no statistically significant association between risk of death and autoantibodies. CONCLUSION: Anticentromere and NUC autoantibodies are prevalent in SSc-PAH patients. An association between serum autoantibodies and survival in patients with SSc-PAH was not identified in the PHAROS cohort.
Authors: Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian Journal: Chest Date: 2010-05-27 Impact factor: 9.410
Authors: N Galiè; M M Hoeper; M Humbert; A Torbicki; J-L Vachiery; J A Barbera; M Beghetti; P Corris; S Gaine; J S Gibbs; M A Gomez-Sanchez; G Jondeau; W Klepetko; C Opitz; A Peacock; L Rubin; M Zellweger; G Simonneau Journal: Eur Respir J Date: 2009-09-12 Impact factor: 16.671
Authors: Mark H Williams; Clive E Handler; Raza Akram; Colette J Smith; Clare Das; Joanna Smee; Devaki Nair; Christopher P Denton; Carol M Black; John G Coghlan Journal: Eur Heart J Date: 2006-04-27 Impact factor: 29.983
Authors: Svetlana I Nihtyanova; Benjamin E Schreiber; Voon H Ong; Daniel Rosenberg; Pia Moinzadeh; J Gerrard Coghlan; Athol U Wells; Christopher P Denton Journal: Arthritis Rheumatol Date: 2014-06 Impact factor: 10.995
Authors: Lorinda Chung; Robyn T Domsic; Bharathi Lingala; Firas Alkassab; Marcy Bolster; M E Csuka; Chris Derk; Aryeh Fischer; Tracy Frech; Daniel E Furst; Mardi Gomberg-Maitland; Monique Hinchcliff; Vivien Hsu; Laura K Hummers; Dinesh Khanna; Thomas A Medsger; Jerry A Molitor; Ioana R Preston; Elena Schiopu; Lee Shapiro; Richard Silver; Robert Simms; John Varga; Jessica K Gordon; Virginia D Steen Journal: Arthritis Care Res (Hoboken) Date: 2014-03 Impact factor: 5.178
Authors: Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-06-07 Impact factor: 5.464
Authors: George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee Journal: Curr Rheumatol Rep Date: 2019-12-07 Impact factor: 4.592
Authors: Roham T Zamanian; David Badesch; Lorinda Chung; Robyn T Domsic; Thomas Medsger; Ashley Pinckney; Lynette Keyes-Elstein; Carla D'Aveta; Meagan Spychala; R James White; Paul M Hassoun; Fernando Torres; Andrew J Sweatt; Jerry A Molitor; Dinesh Khanna; Holden Maecker; Beverly Welch; Ellen Goldmuntz; Mark R Nicolls Journal: Am J Respir Crit Care Med Date: 2021-07-15 Impact factor: 30.528